Molecular Biology of the Pneumococcus (Europneumo) Janine Lux won an award last week at the 16th European Meeting on the Molecular Biology of the Pneumococcus (Europneumo) in Crete for her oral presentation on "AmiA and AliA peptide ligands, found in Klebsiella pneumoniae, are imported into pneumococci and alter the transcriptome".
Stage-Up Winner: Enzoxa The spin-off Enzoxa won the 2023 Bernese start-up comption stage-up. Enzoxa outperforms over 60 other projects in this competition. Enzoxa is a joint venture between the IFIK and IPS consisting of team members: Léa Chèvre, Dr. Matheus Notter, Prof. Christelle Robert, Prof. Siegfried Hapfelmeier, Dr. Pierre Mateo, and Cindy Chen (from left to right). Read more about the stage-up competition in entrepreneurship-bern.ch
«As a researcher I remain sceptical» Olivier Schären is developing a novel vaccine against one of the world's most harmful poultry diseases with the startup Santella. He is one of four young researchers who are being supported in their leap into entrepreneurship as part of the Venture Fellowship Program of the Innovation Office of the University of Bern.
TOP 1-2% Poster Congratulations to Simone Leoni The poster of an improved ex vivo model of tick-borne encephalitis has been successfully accepted for the ECCMID23 congress!
Plant-derived medicines against stomach pathogen Helicobacter pylori Microbial resistance development towards current antibiotics is alarming. New solutions to treat infectious diseases are urgently needed. IFIK Researchers Dr. Matheus Notter, Prof. Siegfried Hapfelmeier, and IPS Researcher Prof. Christelle Robert form the core team of the spin-off project “ENZOXA." The aim is to harness the natural antimicrobial power of plants and develop novel treatments against the stomach pathogen Helicobacter pylori. Read the interview of UniBe Venture Fellow Dr. Notter in UNIAKTUELL.
First UniBE Venture Fellowships have been granted For the first time, the University of Bern has awarded four "UniBE Venture Fellowships" to support entrepreneurial young researchers and their promising innovation projects: two are dedicated to combating antibiotic resistance, one to liver disease therapy and the fourth to improved psychotherapies.
Corona- Forschung in Hochsicherheitslaboren Excerpt from the program "Quinta dimensione. Il futuro è già qui" of the Italian state television RAI with film footage shot in the sitem-insel building. In the feature, Dr. Kathrin Summermatter, head of the Biosafety Center of the Institute for Infectious Diseases (IFIK), comments on corona research in high-security laboratories. The whole program is available in the RAI 3 player (registration required).
Resultate des 501Y-Mutationsscreenings mittels RT-PCR von SARS-CoV-2-positiven Proben, welche im IFIK analysiert wurden.
Biorisk-Manager App Sie finden darin unter anderem Informationen wie eine infektiöse Probe verpackt und transportiert werden muss, wer diese analysieren kann, welche gesetzlichen Bestimmungen es gibt und welche Institutionen weiterhelfen können. Alle darin enthaltenen Daten sind öffentlich zugängliche Informationen. Falls Sie weitere Daten zur Verfügung stellen möchten, oder Änderungswünsche und Korrekturen haben, so bitten wir Sie dies uns unter der E-Mail Adresse info@biorisk.ch zu melden. Dann nehmen wir die Anpassungen gerne vor.
The Institute for Infectious Diseases (IFIK), University of Bern is the first accredited laboratory worldwide to offer nanopore sequencing for the identification of bacteria using nanopore sequencing
Botox-Test on MEA Chip Embryonic Stem Cell-Derived Neurons Grown on Multi-Electrode Arrays as a Novel In vitro Bioassay for the Detection of Clostridium botulinum Neurotoxins. Frontiers in Pharmacology
One Health: Cascading and Microbiome-Dependent Effects on Multitrophic Health – new interdisciplinary project involving 2 IFIK groups.
